| Literature DB >> 35889926 |
Sara Baldassano1, Maria Rita Polizzi1, Leo Sabatino2, Rosalia Caldarella3, Andrea Macaluso4, Angelina Alongi4, Gaetano Felice Caldara4, Vincenzo Ferrantelli4, Sonya Vasto1,5.
Abstract
Micronutrients are required in many reactions involved in physical activity and exercise. Most physically active people do not meet the body's needs in terms of micronutrients through diet. The novelty of the present manuscript is the use of an innovative dietary approach to supply micronutrients to physically active people through biofortified food. Therefore, the key point of this study was to verify whether supplementation with biofortified vegetables-and specifically molybdenum (Mo)-enriched lettuce-in healthy volunteers affects essential regulators of body homeostasis and, specifically, hematological parameters, iron and lipid metabolism, and hepatic function. Twenty-four healthy volunteers were allocated in a double-blinded manner to either a control group that consumed lettuce, or the intervention group, which consumed Mo-enriched lettuce, for 12 days. Blood samples were collected at baseline (T0) and after 12 days (T1). We found that supplementation with Mo-enriched lettuce did not affect hematological parameters, liver function, or lipid metabolism, but significantly improved iron homeostasis by increasing non-binding hemoglobin iron by about 37% and transferrin saturation by about 42%, while proteins of iron metabolism (e.g., transferrin, ferritin, ceruloplasmin) were not affected. The serum molybdenum concentration increased by about 42%. In conclusion, this study shows that consumption of Mo-biofortified lettuce ameliorates iron homeostasis in healthy subjects, and suggests that it could be used as a new nutritional supplementation strategy to avoid iron deficiency in physically active people.Entities:
Keywords: dietary supplements; iron homeostasis; micronutrients; molybdenum; vegetarian diets
Mesh:
Substances:
Year: 2022 PMID: 35889926 PMCID: PMC9320783 DOI: 10.3390/nu14142971
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Characteristics of participants at baseline; n: number of members in the group. Values are indicated as means ± standard deviations (SD); p-values higher than 0.05 mean that the change is not statistically significant.
| Parameters | Control Group Age Range: 23–57 | Intervention Group Age Range: 27–53 | |
|---|---|---|---|
| Age | 37.5 ± 13.5 | 40 ± 10 | >0.05 |
| Height(m) | 1.68 ± 10 | 1.72 ± 9 | >0.05 |
| Weight (Kg) | 69 ± 9.8 | 72 ± 13 | >0.05 |
| BMI (kg/m2) | 24.3 ± 2.5 | 24.2 ± 2.8 | >0.05 |
| Visceral fat (%) | 6.5 ± 3.3 | 7.2 ± 3.2 | >0.05 |
| Fat mass (%) | 28.6 ± 7.3 | 26.5 ± 7.1 | >0.05 |
| Lean mass (%) | 32.8 ± 5.8 | 33.2 ± 5.4 | >0.05 |
| Median age | 38.5 | 39 | >0.05 |
Figure 1Flowchart of the recruitment process during the study period.
Eligibility criteria summary of the study.
| Selection Criteria | Inclusion Criteria | Exclusion Criteria |
|---|---|---|
| Absence of blood-related dysfunction; cardiac, gastrointestinal, and metabolic disorders; recent viral infection; and food allergies | Volunteers of Italian ethnicity | Presence of chronic disease |
| Not taking medications | Age range: 18–60 years | Use of medication |
| Absence of obesity | Clinically healthy | Use of dietary supplements |
| Not taking supplements | Body mass index: 18.5–28 kg/m2 | Breastfeeding, Pregnancy |
Figure 2Flowchart of the nutritional interventional study during the period of 12 days of administration of canasta lettuce, with and without molybdenum biofortification. Green represents the control group, who ate canasta lettuce with no biofortification. Purple represents the treated group, who ate lettuce biofortified with molybdenum. Blood samples were collected at baseline (T0) and at the end of the nutritional intervention (T1).
Hematological profiles in response to the 12-day nutritional intervention with control or Mo-biofortified lettuce. Values are indicated as means ± standard deviations; p-values higher than 0.05 mean that the change is not statistically significant.
| Parameters | Control Group | Intervention Group | ||||
|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | |||||
| T0 | T1 | T0 | T1 | |||
| WBC (103/µL) | 7.3 ± 2.0 | 7.0 ± 2.2 | >0.05 | 7.1 ± 1.3 | 7.5 ± 1.8 | >0.05 |
| NEUT. (%) | 57 ± 6.1 | 54.3 ± 7.2 | >0.05 | 56.7 ± 6.5 | 58.7 ± 9.7 | >0.05 |
| LYMP. (%) | 30.7 ± 3.7 | 34.1 ± 5.1 | >0.05 | 31.7 ± 7.1 | 30.3 ± 9.6 | >0.05 |
| MON. (%) | 8.3 ± 1.8 | 7.9 ± 1.5 | >0.05 | 7.9 ± 0.9 | 7.7 ± 1.1 | >0.05 |
| EOS. (%) | 2.2 ± 1.4 | 2.0 ± 1.0 | >0.05 | 2.8 ± 1.9 | 2.3 ± 1.5 | >0.05 |
| BAS. (%) | 0.7 ± 0.3 | 0.7 ± 0.4 | >0.05 | 0.6 ± 0.3 | 0.7 ± 0.5 | >0.05 |
| NEUT. (103/µL) | 3.5 ± 1.3 | 3.6 ± 1.4 | >0.05 | 3.2 ± 1.0 | 3.1 ± 1.0 | >0.05 |
| LYM. (103/µL) | 2.3 ± 0.8 | 2.4 ± 1.0 | >0.05 | 2.2 ± 0.8 | 2.2 ± 0.8 | >0.05 |
| MON. (103/µL) | 0.6 ± 0.2 | 0.5 ± 0.1 | >0.05 | 0.5 ± 0.2 | 0.6 ± 0.1 | >0.05 |
| EOS. (103/µL) | 0.2 ± 0.2 | 0.2 ± 0.1 | >0.05 | 0.2 ± 0.1 | 0.2 ± 0.1 | >0.05 |
| BAS. (103/µL) | 0.0 ± 0.0 | 0.0 ± 0.0 | >0.05 | 0.0 ± 0.0 | 0.0 ± 0.0 | >0.05 |
| RBC (106/µL) | 4.8 ± 0.6 | 4.8 ± 0.6 | >0.05 | 4.8 ± 1.0 | 4.9 ± 0.6 | >0.05 |
| HGB (g/dL) | 13.9 ± 1.1 | 13.2 ± 1.4 | >0.05 | 14.4 ± 1.8 | 14.0 ± 1.6 | >0.05 |
| HCT % | 39.1 ± 5.3 | 38.7 ± 4.6 | >0.05 | 41.4 ± 6.4 | 40.5 ± 4.5 | >0.05 |
| MCV (fL) | 83.2 ± 6.4 | 81.7 ± 6.7 | >0.05 | 84.5 ± 7.3 | 82.9 ± 7.0 | >0.05 |
| MCH (pg) | 27.6 ± 2.7 | 27.8 ± 2.7 | >0.05 | 28.6 ± 3.2 | 28.7± 2.9 | >0.05 |
| MCHC (g/dL) | 33.1 ± 1.4 | 33.6 ± 1.9 | >0.05 | 33.2 ± 1.8 | 34.1 ± 1.7 | >0.05 |
| RDW (%) | 13.5 ± 1.3 | 13.6 ± 1.3 | >0.05 | 13.5 ± 1.3 | 13.5 ± 1.3 | >0.05 |
| RDW (fL) | 40.0 ± 2.4 | 39.8 ± 2.8 | >0.05 | 40.6 ± 2.9 | 40.2 ± 2.8 | >0.05 |
| PLT (103/µL) | 245.2 ± 42.8 | 232.7 ± 43.3 | >0.05 | 262.0 ± 72.0 | 273.2 ± 47.4 | >0.05 |
Acronyms: HCT, hematocrit; HGB, hemoglobin; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean cell volume; RBC: red blood cells; RDW, red blood cell distribution width; PLT, platelet; WBC, white blood cells.
Figure 3Iron metabolism in response to the 12-day nutritional intervention with control lettuce (green, control group) or Mo-biofortified lettuce (purple, intervention group). Panels show box-and-whisker plots: (A) iron, (B) transferrin saturation, (C) ferritin, (D) transferrin, and (E) ceruloplasmin concentrations taken at baseline (T0) and after 12 days (T1) in the two study groups; p < 0.05 was considered statistically significant. Iron concentration was significantly different in the control group (p = 0.03) with respect to the intervention group at T1, and within the intervention group at T0 (p = 0.01) with respect to T1. Transferrin saturation was significantly different in the control group (p = 0.01) with respect to the intervention group at T1, and within the intervention group at T0 (p = 0.03) with respect to T1.
Liver function in response to the 12-day nutritional intervention with control or Mo-biofortified lettuce. Values are indicated as means ± standard deviations; p-values higher than 0.05 mean that the change is not statistically significant, and indicate strong evidence for the null hypothesis.
| Parameters | Control Group | Intervention Group | ||||
|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | |||||
| T0 | T1 | T0 | T1 | |||
| AST (U/L) | 22.0 ± 4.5 | 19.0 ± 5.0 | >0.05 | 20.7 ± 4.4 | 18.6 ± 6.9 | >0.05 |
| ALT (U/L) | 19.9 ± 11.3 | 20.6 ± 9.1 | >0.05 | 19.3 ± 8.5 | 12.7 ± 4.9 | >0.05 |
| ALP (U/L) | 63.0 ± 10.0 | 58.5 ± 10.9 | >0.05 | 65.5 ± 11.6 | 59.4 ± 8.8 | >0.05 |
| GGT (U/L) | 15.2 ± 6.2 | 14.7 ± 5.1 | >0.05 | 15.7 ± 6.4 | 15.7 ± 6.4 | >0.05 |
| TP (g/L) | 71.1 ± 3.0 | 70.8 ± 3.9 | >0.05 | 71.4 ± 2.9 | 70.7 ± 3.7 | >0.05 |
| ALB (g/L) | 45.5 ± 3.5 | 46.5 ± 2.7 | >0.05 | 44.1 ± 2.3 | 46.7 ± 2.7 | >0.05 |
Acronyms: AST, aspartate aminotransferase; ALT, alanine transaminase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; TP, total protein; ALB, albumin.
Lipid profiles in response to the 12-day nutritional intervention with control or Mo-biofortified lettuce. Values are indicated as means ± standard deviations; p-values higher than 0.05 mean that the change is not statistically significant, and indicate strong evidence for the null hypothesis.
| Parameters | Control Group | Intervention Group | ||||
|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | |||||
| T0 | T1 | T0 | T1 | |||
| TG (mg/dL) | 84.7± 45.6 | 81.5 ± 28.6 | >0.05 | 89.0 ± 36.8 | 87.0 ± 40.9 | >0.05 |
| CHOL TOT (mg/dL) | 167.9 ± 23.6 | 166.9 ± 27.8 | >0.05 | 174.2 ± 23.0 | 173.7 ± 23.0 | >0.05 |
| CHOL LDL (mg/dL) | 96.9 ± 22.4 | 97.2 ± 28.0 | >0.05 | 102.1 ± 17.7 | 104.2 ± 28.8 | >0.05 |
| CHOL HDL (mg/dL) | 49.1 ± 7.00 | 47.2 ± 7.5 | >0.05 | 55.3 ± 15.6 | 56.1 ± 16 | >0.05 |
Acronyms: TG, triglycerides; CHOL, cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Serum molybdenum concentrations (μg/L).
| Control Group | Intervention Group | ||
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| T0 | T1 | T0 | T1 |
| 4.9 ± 1.6 μg/L | 5.1 ± 1.7 μg/L | 5.0 ± 1.7 μg/L | 7.1* ± 1.5 μg/L |
p-Values lower than 0.05 mean that the change is statistically significant, and are indicated by asterisks. Asterisks denote significant differences compared to T0 and T1of the control group and T0 of the intervention group with respect to T1 of the intervention group; n = 12 in each group.